Selank vs a Benzodiazepine: What a 14-Day Human Trial Showed

Benzodiazepines work. That has never been the problem. The problem is sedation, tolerance, dependence, cognitive dulling and withdrawal — which is why researchers have spent four decades looking for anxiolytic mechanisms that don't run straight through the benzodiazepine receptor site.

Selank has been quietly part of that search since the 1990s, and the most interesting data point is a head-to-head human comparison that rarely gets cited in English-language discussion.

What Selank is

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Russia, derived from the endogenous immunomodulatory peptide tuftsin.

It's studied simultaneously as an anxiolytic, a nootropic and an immunomodulator, which is unusual. Proposed mechanisms include:

• GABAergic modulation
• Regulation of enkephalin-degrading enzyme activity
• Serotonergic and dopaminergic signalling
• Effects on BDNF expression
• Immune signalling interactions

That multi-target profile is the reason it behaves differently from a classical anxiolytic in study models.

The trial

The study — Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia — enrolled 62 participants with generalised anxiety disorder or neurasthenia.

• Selank group: 30 participants
• Medazepam (benzodiazepine) group: 32 participants
• Duration: 14 days
• Instruments: Hamilton Anxiety Scale, Zung Self-Rating Anxiety Scale, Clinical Global Impression
• Biomarker: serum enkephalin activity

The result

After two weeks, Selank's anxiolytic effect was comparable to medazepam.

Both groups improved on anxiety scales. That alone would be interesting for a peptide with no benzodiazepine-site activity. The differences appeared in the secondary observations.

Antiasthenic effects. Participants on Selank reported improvement in fatigue and mental exhaustion — the opposite direction to the sedation typically seen with benzodiazepines.

Mild psychostimulant character. Rather than blunting daytime performance, Selank was associated with preserved or improved mental function.

Enkephalin activity. Researchers observed changes in serum enkephalin degradation, offering a plausible biochemical mechanism rather than a purely behavioural observation.

Autonomic symptoms. Improvements were noted in the physical, autonomic components of anxiety.

The caveats, stated plainly

• Single study, modest sample size
• Published in Russian literature with limited independent replication
• Fourteen days tells you nothing about long-term use or withdrawal characteristics
• No placebo arm — this was active comparator only
• Study models differ from the way the compound is discussed online

Why it still matters

Most peptide anxiolytic discussion is preclinical. This is one of the few instances where a peptide was placed beside a clinically established drug in humans, on validated scales, and did not embarrass itself.

That justifies more rigorous work. It does not justify treating a 62-person, two-week, single-country study as settled science — a distinction the research community is generally better at making than the internet is.

Selank is also frequently studied alongside Semax, which targets complementary neurochemical systems. Both are in the EVERKIND range for laboratory research use.

Disclaimer: This article is educational only. All compounds discussed are supplied strictly for laboratory research use and are not approved for human or veterinary use.